BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22102868)

  • 1. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma.
    Seitz V; Butzhammer P; Hirsch B; Hecht J; Gütgemann I; Ehlers A; Lenze D; Oker E; Sommerfeld A; von der Wall E; König C; Zinser C; Spang R; Hummel M
    PLoS One; 2011; 6(11):e26837. PubMed ID: 22102868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
    Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
    Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells.
    Doose G; Haake A; Bernhart SH; López C; Duggimpudi S; Wojciech F; Bergmann AK; Borkhardt A; Burkhardt B; Claviez A; Dimitrova L; Haas S; Hoell JI; Hummel M; Karsch D; Klapper W; Kleo K; Kretzmer H; Kreuz M; Küppers R; Lawerenz C; Lenze D; Loeffler M; Mantovani-Löffler L; Möller P; Ott G; Richter J; Rohde M; Rosenstiel P; Rosenwald A; Schilhabel M; Schneider M; Scholz I; Stilgenbauer S; Stunnenberg HG; Szczepanowski M; Trümper L; Weniger MA; ; Hoffmann S; Siebert R; Iaccarino I
    Proc Natl Acad Sci U S A; 2015 Sep; 112(38):E5261-70. PubMed ID: 26351698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma.
    Oduor CI; Kaymaz Y; Chelimo K; Otieno JA; Ong'echa JM; Moormann AM; Bailey JA
    BMC Cancer; 2017 Nov; 17(1):761. PubMed ID: 29132323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
    Onnis A; De Falco G; Antonicelli G; Onorati M; Bellan C; Sherman O; Sayed S; Leoncini L
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20930934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
    Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
    Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.
    Yoon JW; Gallant M; Lamm ML; Iannaccone S; Vieux KF; Proytcheva M; Hyjek E; Iannaccone P; Walterhouse D
    Mol Cancer Res; 2013 Jun; 11(6):604-15. PubMed ID: 23525267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.
    Li Z; Van Calcar S; Qu C; Cavenee WK; Zhang MQ; Ren B
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8164-9. PubMed ID: 12808131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors.
    De Falco G; Leucci E; Lenze D; Piccaluga PP; Claudio PP; Onnis A; Cerino G; Nyagol J; Mwanda W; Bellan C; Hummel M; Pileri S; Tosi P; Stein H; Giordano A; Leoncini L
    Blood; 2007 Aug; 110(4):1301-7. PubMed ID: 17485552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A c-Myc regulatory subnetwork from human transposable element sequences.
    Wang J; Bowen NJ; Mariño-Ramírez L; Jordan IK
    Mol Biosyst; 2009 Dec; 5(12):1831-9. PubMed ID: 19763338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
    Karkhanis V; Alinari L; Ozer HG; Chung J; Zhang X; Sif S; Baiocchi RA
    J Biol Chem; 2020 Jan; 295(5):1165-1180. PubMed ID: 31822509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Myc Chromatin Binding by Calibrated ChIP-Seq Approach.
    Cameron DP; Kuzin V; Baranello L
    Methods Mol Biol; 2021; 2318():161-185. PubMed ID: 34019290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
    Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
    J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
    Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
    J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.
    Schlee M; Hölzel M; Bernard S; Mailhammer R; Schuhmacher M; Reschke J; Eick D; Marinkovic D; Wirth T; Rosenwald A; Staudt LM; Eilers M; Baran-Marszak F; Fagard R; Feuillard J; Laux G; Bornkamm GW
    Int J Cancer; 2007 Apr; 120(7):1387-95. PubMed ID: 17211884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.
    Hüttl KS; Staiger AM; Richter J; Ott MM; Kalmbach S; Klapper W; Biesdorf AS; Trümper L; Rosenwald A; Ziepert M; Horn H; Ott G
    Virchows Arch; 2021 Sep; 479(3):575-583. PubMed ID: 33655392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
    Rodig SJ; Kutok JL; Paterson JC; Nitta H; Zhang W; Chapuy B; Tumwine LK; Montes-Moreno S; Agostinelli C; Johnson NA; Ben-Neriah S; Farinha P; Shipp MA; Piris MA; Grogan TM; Pileri SA; Gascoyne RD; Marafioti T
    Haematologica; 2010 Dec; 95(12):2056-62. PubMed ID: 20823132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network and Computational Drug Repurposing Analysis for c-Myc Inhibition in Burkitt Lymphoma.
    Lee Y; Nam S
    Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):712-722. PubMed ID: 38035700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
    Lindström MS; Klangby U; Wiman KG
    Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.